Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose Non-Fermentable (SWI/SNF) alterations who have already been treated with FOLFIRINOX (5-fluoruracil, leucovorin, irinotecan, oxaliplatin) or gemcitabine/nab-paclitaxel chemotherapy.

Trial Details

NCT ID
NCT06790602
Phase
PHASE2
Sponsor
University of California, San Diego
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • Cemiplimab Plus Gemcitabine
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742

Key Eligibility Criteria

  • At least 18 years of age.
  • Ability to understand the nature of this study, comply with study and follow-up procedures, and give written informed consent.
  • Histologically or cytologically confirmed pancreatic ductal adenocarcinoma. Primary tumor can be intact or post-resection with newly developed meta…
  • Stage IV disease (measurable disease by Immunotherapeutics Response Evaluation Criteria in Solid Tumors is required).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →